APO RESEARCH · REPORT
Generic Injectables
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
Product & engineering
Understand the product.
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
Selected research
Industry Research
Generic Injectables Industry Research Report 2026
Market perspective
Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.
In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.
Read the full market overview
Report Scope
This report quantifies the global Generic Injectables market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Generic Injectables.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Generic Injectables Market by Company
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC
Generic Injectables Segment by Type
Small Molecule
Large Molecule
Generic Injectables Segment by Application
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases
Generic Injectables Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecule
- Large Molecule
Applications
- Oncology
- Anesthesia
- Anti-Infectives
- Parenteral Nutrition
- Cardiovascular Diseases
Companies covered
- Hospira (Pfizer Inc.)
- Fresenius Kabi
- Sandoz (Novartis)
- Hikma Pharmaceuticals PLC
- Dr. Reddy’s Laboratories Ltd
- Grifols
- Nichi-Iko Group (Sagent)
- Teva Pharmaceutical
- Auromedics
- Sanofi
- Gland Pharma
- Endo International PLC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Generic Injectables by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Small Molecule
- 2.2.3 Large Molecule
- 2.3 Generic Injectables by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Anesthesia
- 2.3.4 Anti-Infectives
- 2.3.5 Parenteral Nutrition
- 2.3.6 Cardiovascular Diseases
- 2.4 Assumptions and Limitations
3 Generic Injectables Breakdown Data by Type
- 3.1 Global Generic Injectables Historic Market Size by Type (2021-2026)
- 3.2 Global Generic Injectables Forecasted Market Size by Type (2027-2032)
4 Generic Injectables Breakdown Data by Application
- 4.1 Global Generic Injectables Historic Market Size by Application (2021-2026)
- 4.2 Global Generic Injectables Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Generic Injectables Market Perspective (2021-2032)
- 5.2 Global Generic Injectables Growth Trends by Region
- 5.2.1 Global Generic Injectables Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Generic Injectables Historic Market Size by Region (2021-2026)
- 5.2.3 Generic Injectables Forecasted Market Size by Region (2027-2032)
- 5.3 Generic Injectables Market Dynamics
- 5.3.1 Generic Injectables Industry Trends
- 5.3.2 Generic Injectables Market Drivers
- 5.3.3 Generic Injectables Market Challenges
- 5.3.4 Generic Injectables Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Generic Injectables Players by Revenue
- 6.1.1 Global Top Generic Injectables Players by Revenue (2021-2026)
- 6.1.2 Global Generic Injectables Revenue Market Share by Players (2021-2026)
- 6.2 Global Generic Injectables Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Generic Injectables Head Office and Area Served
- 6.4 Global Generic Injectables Players, Product Type & Application
- 6.5 Global Generic Injectables Manufacturers Established Date
- 6.6 Global Generic Injectables Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Generic Injectables Market Size (2021-2032)
- 7.2 North America Generic Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Generic Injectables Market Size by Country (2021-2026)
- 7.4 North America Generic Injectables Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Generic Injectables Market Size (2021-2032)
- 8.2 Europe Generic Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Generic Injectables Market Size by Country (2021-2026)
- 8.4 Europe Generic Injectables Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Generic Injectables Market Size (2021-2032)
- 9.2 Asia-Pacific Generic Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Generic Injectables Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Generic Injectables Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Generic Injectables Market Size (2021-2032)
- 10.2 South America Generic Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Generic Injectables Market Size by Country (2021-2026)
- 10.4 South America Generic Injectables Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Generic Injectables Market Size (2021-2032)
- 11.2 Middle East & Africa Generic Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Generic Injectables Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Generic Injectables Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Hospira (Pfizer Inc.)
- 12.1.1 Hospira (Pfizer Inc.) Company Information
- 12.1.2 Hospira (Pfizer Inc.) Business Overview
- 12.1.3 Hospira (Pfizer Inc.) Revenue in Generic Injectables Business (2021-2026)
- 12.1.4 Hospira (Pfizer Inc.) Generic Injectables Product Portfolio
- 12.1.5 Hospira (Pfizer Inc.) Recent Developments
- 12.2 Fresenius Kabi
- 12.2.1 Fresenius Kabi Company Information
- 12.2.2 Fresenius Kabi Business Overview
- 12.2.3 Fresenius Kabi Revenue in Generic Injectables Business (2021-2026)
- 12.2.4 Fresenius Kabi Generic Injectables Product Portfolio
- 12.2.5 Fresenius Kabi Recent Developments
- 12.3 Sandoz (Novartis)
- 12.3.1 Sandoz (Novartis) Company Information
- 12.3.2 Sandoz (Novartis) Business Overview
- 12.3.3 Sandoz (Novartis) Revenue in Generic Injectables Business (2021-2026)
- 12.3.4 Sandoz (Novartis) Generic Injectables Product Portfolio
- 12.3.5 Sandoz (Novartis) Recent Developments
- 12.4 Hikma Pharmaceuticals PLC
- 12.4.1 Hikma Pharmaceuticals PLC Company Information
- 12.4.2 Hikma Pharmaceuticals PLC Business Overview
- 12.4.3 Hikma Pharmaceuticals PLC Revenue in Generic Injectables Business (2021-2026)
- 12.4.4 Hikma Pharmaceuticals PLC Generic Injectables Product Portfolio
- 12.4.5 Hikma Pharmaceuticals PLC Recent Developments
- 12.5 Dr. Reddy’s Laboratories Ltd
- 12.5.1 Dr. Reddy’s Laboratories Ltd Company Information
- 12.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
- 12.5.3 Dr. Reddy’s Laboratories Ltd Revenue in Generic Injectables Business (2021-2026)
- 12.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Product Portfolio
- 12.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
- 12.6 Grifols
- 12.6.1 Grifols Company Information
- 12.6.2 Grifols Business Overview
- 12.6.3 Grifols Revenue in Generic Injectables Business (2021-2026)
- 12.6.4 Grifols Generic Injectables Product Portfolio
- 12.6.5 Grifols Recent Developments
- 12.7 Nichi-Iko Group (Sagent)
- 12.7.1 Nichi-Iko Group (Sagent) Company Information
- 12.7.2 Nichi-Iko Group (Sagent) Business Overview
- 12.7.3 Nichi-Iko Group (Sagent) Revenue in Generic Injectables Business (2021-2026)
- 12.7.4 Nichi-Iko Group (Sagent) Generic Injectables Product Portfolio
- 12.7.5 Nichi-Iko Group (Sagent) Recent Developments
- 12.8 Teva Pharmaceutical
- 12.8.1 Teva Pharmaceutical Company Information
- 12.8.2 Teva Pharmaceutical Business Overview
- 12.8.3 Teva Pharmaceutical Revenue in Generic Injectables Business (2021-2026)
- 12.8.4 Teva Pharmaceutical Generic Injectables Product Portfolio
- 12.8.5 Teva Pharmaceutical Recent Developments
- 12.9 Auromedics
- 12.9.1 Auromedics Company Information
- 12.9.2 Auromedics Business Overview
- 12.9.3 Auromedics Revenue in Generic Injectables Business (2021-2026)
- 12.9.4 Auromedics Generic Injectables Product Portfolio
- 12.9.5 Auromedics Recent Developments
- 12.10 Sanofi
- 12.10.1 Sanofi Company Information
- 12.10.2 Sanofi Business Overview
- 12.10.3 Sanofi Revenue in Generic Injectables Business (2021-2026)
- 12.10.4 Sanofi Generic Injectables Product Portfolio
- 12.10.5 Sanofi Recent Developments
- 12.11 Gland Pharma
- 12.11.1 Gland Pharma Company Information
- 12.11.2 Gland Pharma Business Overview
- 12.11.3 Gland Pharma Revenue in Generic Injectables Business (2021-2026)
- 12.11.4 Gland Pharma Generic Injectables Product Portfolio
- 12.11.5 Gland Pharma Recent Developments
- 12.12 Endo International PLC
- 12.12.1 Endo International PLC Company Information
- 12.12.2 Endo International PLC Business Overview
- 12.12.3 Endo International PLC Revenue in Generic Injectables Business (2021-2026)
- 12.12.4 Endo International PLC Generic Injectables Product Portfolio
- 12.12.5 Endo International PLC Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst